

those patients under 30 years of age referred for any cytological alteration are studied, and that after colposcopy and biopsy a result of CIN II – CIN III is obtained. . Only those patients treated by conization have been selected.

Results A total of 10 patients were included in the study. Of the patients in whom the cervical biopsy after colposcopy showed CIN-II (7 patients), 85.7% (N=6) presented CIN-II in the conization specimen and 14.3% (N=1) presented CIN - YO. Of those who had CIN-III in the postcolposcopy biopsy (3 patients), 66.7% (N=2) presented CIN-II in the conization piece and 33.3% (N=1) presented moderately differentiated infiltrating squamous cell carcinoma with resection ends widely affected by neoplasia.

Conclusion The presence of preinvasive lesions in women under 30 years of age is a health problem in our environment. Perhaps we should investigate more on this topic to find some evidence that leads us to an action plan that leads to change.

2022-RA-661-ESGO

CONTRIBUTION OF INTERSTITIAL NEEDLES DURING IMAGE GUIDED BRACHYTHERAPY IGBT AFTER RADIOCHEMOTHERAPY RCT IN THE MANAGEMENT OF LOCALLY ADVANCED CERVICAL CANCER LACC

Cordoba Abel. *Radiation Oncology, Centre Oscar Lambret, Lille, France*

10.1136/ijgc-2022-ESGO.44

Introduction/Background Evaluate benefit with interstitial (IC/IS) IGBT in terms on dose on target volume while managing LACC, after external RCT, compared to treatment with only intracavitary (IC) IGBT.

Methodology All patients were treated with IC/IS IGBT after RCT. IC/IS IGBT was compared to IC IGBT for target volume cover (GTV, HR-CTV, IR-CTV). We evaluated overall survival, local control and toxicity with IC/IS IGBT. Local control was analysed by years of treatment to assess improvement over time.

Results From 01/2017 to 12/2020, 99 patients (p) were analysed. FIGO 2009 classification: IIA 6p, IIB 45p, IIIB 22p, IVA 20p, IVB 6p. FIGO 2018 founded 24p IIIC1 and 28p IIIC2. Mean High Risk Clinical Target Volume (HRCTV) was 40 cm³ (9,6–103) with 66 (66,7%) patients presented a volume >30cc. The median Overall treatment Time (OTT) was 55 days (50 – 62). The mean D90 HR-CTV was 80,3Gy for patients treated by IC/IS, and 75,1Gy for IC (p<0.0001). A decrease of the delivered dose for all Organs at Risk (OAR) was found: D₂ Bladder less than 80Gy to IC/IS in 66,7% of patients and 27,3% of patients without IS (p<0,0001); D₂ Rectum is less 65Gy in 32,3% of patients with IC/IS and 17,2% of patients without (p<0,001); and D₂ Sigmoid is less than 70Gy in 99% of patients with IC/IS and in 94,9% of patients without (p<0,05). The overall survival (OS) was 66,2% at 2 years, and local control (LC) was 56,5% at 2 years. Local survival improved over time, with better control in 2020 (p=0,036).

Conclusion Dose to HRCTV is higher with IC/IS IGBT compared to IC IGBT with lower doses to OAR in patients managed for LACC after RCT

2022-RA-678-ESGO

CONTESSA/NEOCON-F TRIAL: ASSESSING THE EFFECTIVENESS AND SAFETY OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY FERTILITY-SPARING SURGERY IN FIGO 2018 STAGE IB2 CERVICAL CANCER

¹Marie Plante, ^{2,3}Nienke E van Trommel, ^{2,4}Mirte Schaafsma, ⁵Amit M Oza, ⁶Angela Rodriguez, ⁷Lisa Wang, ⁸Karolina Sikorska, ⁹Sarah E Ferguson, ¹⁰Kathy Han, ⁵Stephanie Lheureux, ^{2,11,3}Frédéric Amant. ¹Obstetrics and Gynecology, Centre Hospitalier Universitaire de Quebec, Quebec City, QC, Canada; ²Gynecologic Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, Amsterdam, Netherlands; ³Gynecologic Oncology, Center for Gynecologic Oncology Amsterdam, Amsterdam, Netherlands; ⁴Pathology, Amsterdam UMC, Amsterdam, Netherlands; ⁵Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; ⁶BRAS Drug Development Program, Princess Margaret Cancer Centre, Toronto, ON, Canada; ⁷Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada; ⁸Biostatistics, Antoni van Leeuwenhoek/Netherlands Cancer Institute, Amsterdam, Netherlands; ⁹Gynecologic Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada; ¹⁰Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada; ¹¹Gynecologic Oncology, Amsterdam UMC, Amsterdam, Netherlands

10.1136/ijgc-2022-ESGO.45

Introduction/Background The optimal management of FIGO 2018 stage IB2 cervical cancer patients who desire to preserve fertility is unknown. Therefore, the CONTESSA/NEOCON-F trial (NCT04016389) aims to evaluate a promising, new fertility-sparing treatment: neoadjuvant chemotherapy (NACT) followed by fertility-sparing surgery (FSS).

Methodology This trial is an ongoing, phase II clinical trial, which will accrue 90 pre-menopausal, lymph-node negative, FIGO 2018 stage IB2 cervical cancer patients, aged between 18 and 40 years and who desire to preserve their fertility. All patients will receive three cycles of paclitaxel and platinum containing chemotherapy. Following NACT the response will be evaluated by clinical examination and MRI. Patients must achieve a complete or partial response (residual lesion <2 cm) to be eligible for FSS: a conisation or simple trachelectomy. Patients with suboptimal response (residual lesion ≥2 cm) will go off-study and receive definitive treatment, radical hysterectomy or chemoradiation as per local protocol. Patients will be followed for three years following FSS. The safety of this trial will be continuously monitored using Bayesian posterior probability and the stopping rule will be activated if there is at least 70% probability that two-year recurrence rate is above 10%.

Results The primary outcome is the rate of functional uterus defined as successful FSS and no need for adjuvant therapy post procedure. Secondary outcomes include the safety of the treatment, the response rate to NACT, and the recurrence-free and overall survival after two and three years. Finally, this trial will also explore the effect of NACT on ovarian function. Translational research will explore disease monitoring in blood plasma (HPV ctDNA) and cervical scrapes (DNA hypermethylation), and patients' quality of life will be assessed by questionnaires.

Conclusion The CONTESSA/NEOCON-F trial is opened for accrual in the Netherlands, Canada, and the United States. Currently, 10% of the target accrual has been reached.